| Literature DB >> 35437922 |
Shun Ito1, Kazuo Kobayashi1,2, Keiichi Chin1, Shinichi Umezawa1, Hareaki Yamamoto1, Shiro Nakano1, Nobukazu Takada1, Nobuo Hatori3, Kouichi Tamura2.
Abstract
AIMS/Entities:
Keywords: Blood pressure; Coronavirus disease 2019; Diabetes mellitus
Mesh:
Substances:
Year: 2022 PMID: 35437922 PMCID: PMC9114982 DOI: 10.1111/jdi.13813
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 3.681
Clinical characteristics of 310 cases during the state of emergency due to coronavirus disease 2019
| Characteristics of patients | |
| Male (%) | 197 (64%) |
| Age (years) | 68.6 ± 11.3 (range 28–93) |
| Hypertension | 300 (97%) |
| Dyslipidemia | 299 (97%) |
| Chronic kidney disease | 190 (61%) |
| Cardiovascular disease | 74 (24%) |
| Cerebrovascular disease | 25 (8%) |
| Current medications during the state of emergency | |
| Antihypertensive agents | |
| ARB | 169 (55%) |
| ACEI | 25 (8%) |
| Ca channel blocker | 146 (47%) |
| β‐Blocker | 50 (16%) |
| Thiazide | 13 (4%) |
| Mineralocorticoid receptor blocker | 23 (7%) |
| Loop diuretic | 5 (2%) |
| Hypoglycemic agents | |
| DPP4 inhibitor | 137 (44%) |
| Metformin | 89 (29%) |
| SGLT2 inhibitor | 63 (20%) |
| Insulin | 48 (16%) |
| Sulphonyl urea | 59 (19%) |
| GLP‐1 receptor agonist | 20 (7%) |
| Pioglitazone | 32 (10%) |
| α‐Glucosidase inhibitor | 65 (21%) |
| Glinide | 30 (10%) |
| Others | |
| Statin | 255 (82%) |
| Ezetimibe | 60 (19%) |
| Antiplatelet | 77 (25%) |
Data shown are numbers (%).
ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; COVID‐19, coronavirus disease 2019; DPP4, dipeptidyl peptidase‐4; GLP‐1, glucagon‐like peptide‐1; SGLT2, sodium–glucose cotransporter 2.
Change in clinical findings before and after the announcement of the state of emergency due to coronavirus disease 2019
| Total ( | January to March 2020 | During the state of emergency |
|
|---|---|---|---|
| BW (kg) | 65.0 ± 12.4 | 64.8 ± 12.5 | 0.17 |
| BMI ( | 24.5 ± 3.7 | 24.4 ± 3.7 | 0.31 |
| Office‐SBP (mmHg) | 139.3 ± 19.0 | 141.6 ± 18.6 | 0.02 |
| Office‐DBP (mmHg) | 77.5 ± 12.4 | 78.8 ± 11.9 | 0.03 |
| Office‐MAP (mmHg) | 98.0 ± 12.8 | 99.7 ± 12.2 | 0.01 |
| Pulse rate ( | 80.1 ± 13.8 | 80.0 ± 13.1 | 0.85 |
| Home‐SBP (mmHg) ( | 128.6 ± 8.9 | 127.5 ± 8.9 | 0.01 |
| Home‐DBP (mmHg) ( | 74.9 ± 8.6 | 74.4 ± 8.5 | 0.08 |
| Home‐MAP (mmHg) ( | 92.8 ± 7.6 | 92.8 ± 7.6 | 0.02 |
| eGFR (mL/min/1.73 m2) | 68.9 ± 19.8 | 68.1 ± 19.3 | 0.08 |
| HbA1c (mmol/mol [%]) | 51.0 ± 10.3 (6.8 ± 0.9) | 51.4 ± 10.1 (6.9 ± 0.9) | 0.19 |
| ACR (mg/gCr) | 10.1 [4.9–22.9] | 9.5 [5.3–24.0] | 0.51 |
| Logarithmic value of ACR | 1.31 ± 0.07 | 1.25 ± 0.07 | 0.23 |
| Estimated sodium intake, g/day ( | 9.4 [7.9–10.8] | 9.1 [7.4–10.7] | 0.36 |
Data shown as the mean ± standard deviation or median [lower quartile, upper quartile].
Paired t‐test.
Wilcoxon signed‐rank test.
ACR, urine albumin‐to‐creatinine ratio; BMI, body mass index; BW, body weight; COVID‐19, coronavirus disease 2019; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; MAP, mean arterial pressure; SBP, systolic blood pressure.
Questions related to the change in stress after the state of emergency
| Q1. Do you worry about adverse effects of hypertension as a contributing condition to the severity and poor prognosis of COVID‐19? | ||||||
|---|---|---|---|---|---|---|
| No, never | Yes, a little | Neither yes or no | Yes, moderately | Yes, strongly | No answer | |
| 10 (3%) | 77 (25%) | 17 (5%) | 113 (37%) | 80 (26%) | 13 (4%) | |
COVID‐19, coronavirus disease 2019.
Clinical characteristics of patients in both groups before and after propensity score matching
| Unmatched cohort model | Matched cohort model | |||||
|---|---|---|---|---|---|---|
| ΔBP ≤0 | ΔBP >0 |
| ΔBP ≤0 | ΔBP >0 | Standardized difference | |
|
|
|
|
| |||
| Age | 67.8 ± 10.4 | 69.3 ± 12.0 | 0.24 | 68.8 ± 10.0 | 68.5 ± 12.1 | 0.03 |
| Sex (male) | 95 (65%) | 102 (62%) | 0.60 | 67 (63%) | 67 (63%) | 0.0 |
| Hypertension | 142 (97%) | 158 (96%) | 0.65 | 102 (96%) | 103 (97%) | 0.05 |
| Dyslipidemia | 140 (96%) | 159 (97%) | 0.61 | 102 (96%) | 102 (96%) | 0.0 |
| Chronic kidney disease | 86 (59%) | 104 (63%) | 0.42 | 61 (58%) | 61 (58%) | 0.0 |
| Cardiovascular disease | 26 (28%) | 48 (29%) | 0.02 | 22 (21%) | 20 (19%) | 0.05 |
| SBP | 144.8 ± 18.4 | 134.3 ± 18.2 | <0.001 | 139.9 ± 15.5 | 139.7 ± 17.1 | 0.01 |
| DBP | 81.5 ± 12.6 | 73.9 ± 11.1 | <0.001 | 77.7 ± 10.9 | 77.6 ± 9.9 | 0.01 |
| MAP | 102.6 ± 13.0 | 94.0 ± 11.3 | <0.001 | 98.4 ± 10.7 | 98.3 ± 9.6 | 0.01 |
| BW | 65.6 ± 12.5 | 64.4 ± 12.3 | 0.40 | 64.2 ± 11.7 | 64.6 ± 12.9 | 0.03 |
| eGFR | 70.4 ± 20.6 | 67.6 ± 19.0 | 0.21 | 68.8 ± 19.8 | 69.5 ± 19.7 | 0.04 |
| HbA1c | 50.8 ± 1.0 (6.8 ± 0.9) | 51.3 ± 10.8 (6.8 ± 1.0) | 0.68 | 51.1 ± 9.6 (6.8 ± 0.9) | 50.9 ± 10.4 (6.8 ± 1.0) | 0.02 |
| LnACR | 2.48 ± 1.21 | 2.48 ± 1.41 | 0.99 | 2.49 ± 1.24 | 2.47 ± 1.51 | 0.01 |
| Salt intake | 9.6 ± 2.0 ( | 9.2 ± 2.0 ( | 0.10 | 9.5 ± 2.1 ( | 9.1 ± 2.0 ( | |
| Antihypertensive agents | ||||||
| ARB | 82 (56%) | 87 (53%) | 0.58 | 58 (55%) | 58 (55%) | 0.0 |
| ACEI | 9 (6%) | 16 (10%) | 0.25 | 7 (7%) | 7 (7%) | 0.0 |
| Ca channel blocker | 70 (48%) | 76 (46%) | 0.78 | 51 (%) | 47 (44%) | 0.08 |
| β‐Blocker | 22 (15%) | 28 (17%) | 0.63 | 16 (15%) | 13 (12%) | 0.08 |
| Thiazide | 6 (4%) | 7 (4%) | 0.95 | 5 (5%) | 4 (4%) | 0.05 |
| Mineralocorticoid receptor blocker | 11 (8%) | 12 (7%) | 0.94 | 5 (5%) | 5 (5%) | 0.0 |
| Loop diuretic | 2 (1%) | 3 (22%) | 0.75 | 1 (1%) | 2 (2%) | 0.08 |
| Hypoglycemic agents | ||||||
| DPP4 inhibitor | 68 (47%) | 69 (42%) | 0.43 | 46 (44%) | 47 (44%) | 0.02 |
| Metformin | 41 (28%) | 48 29 (%) | 0.82 | 31 (29%) | 30 (28%) | 0.02 |
| SGLT2 inhibitor | 32 (22%) | 31 (19%) | 0.51 | 21 (20%) | 20 (20%) | 0.02 |
| Insulin | 22 (15%) | 26 (16%) | 0.85 | 17 (16%) | 12 (11%) | 0.14 |
| Sulfonylurea | 27 (19%) | 32 (20%) | 0.82 | 17 (16%) | 19 (18%) | 0.05 |
| GLP‐1 receptor agonist | 9 (6%) | 11 (7%) | 0.85 | 8 (8%) | 9 (9%) | 0.03 |
| Pioglitazone | 16 (11%) | 16 (10%) | 0.73 | 11 (10%) | 11 (10%) | 0.0 |
| α‐Glucosidase inhibitor | 28 (19%) | 37 (23%) | 0.47 | 21 (20%) | 21 (20%) | 0.0 |
| Glinide | 16 (11%) | 14 (9%) | 0.47 | 12 (11%) | 10 (9%) | 0.06 |
| Statin | 120 (83%) | 135 (82%) | 0.98 | 88 (83%) | 83 (78%) | 0.12 |
| Ezetimibe | 27 (19%) | 33 (20%) | 0.72 | 18 (17%) | 19 (18%) | 0.02 |
| Antiplatelet | 34 (23%) | 43 (26%) | 0.55 | 27 (26%) | 24 (23%) | 0.07 |
Data shown are shown as the mean ± standard deviation, or numbers (%).
Unpaired t‐test.
χ2‐test.
ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BW, bodyweight; COVID‐19, coronavirus disease 2019; DBP, diastolic blood pressure; DPP4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; GLP‐1, glucagon‐like peptide‐1; HbA1c, hemoglobin A1c; LnACR, logarithmic value of urine albumin‐to creatinine ratio; MAP, mean arterial pressure; SBP, systolic blood pressure; SGLT2, sodium–glucose cotransporter 2.
Ratios of the worsening of each stress and the clinical findings after a state of emergency
| ΔBP ≤0 ( | ΔBP >0 ( |
| |
|---|---|---|---|
| Ratios of the worsening of each stress | |||
| Daily stress | 43 (41%) | 53 (50%) | 0.29 |
| Diet intake | 9 (9%) | 21 (20%) | 0.02 |
| Salt intake | 3 (3%) | 11 (10%) | 0.04 |
| Frequency of lunch or dinner at home | 4 (4%) | 2 (2%) | 0.86 |
| Amount of exercise | 31 (29%) | 43(41%) | 0.14 |
| Quality of sleep | 17 (16%) | 18(17%) | 1.0 |
| Alcohol intake | 1 (1%) | 3(3%) | 0.63 |
| Adherence to taking medications | 3 (3%) | 8(8%) | 0.18 |
| Total stress score | 0.05 ± 2.61 | 0.93 ± 2.7 | 0.03 |
| Clinical findings after a state of emergency | |||
| SBP | 130.6 ± 14.3 | 150.1 ± 16.4 | <0.001 |
| DBP | 72.2 ± 10.7 | 85.1 ± 10.6 | <0.001 |
| MAP | 91.6 ± 10.2 | 106.8 ± 10.3 | <0.001 |
| BW | 64.1 ± 11.7 | 64.6 ± 13.0 | 0.77 |
| eGFR | 67.6 ± 19.7 | 69.7 ± 19.2 | 0.44 |
| HbA1c | 51.1 ± 9.4 (6.8 ± 0.0.9) | 51.7 ± 10.1 (6.9 ± 0.9) | 0.67 |
| LnACR | 2.42 ± 1.20 | 2.64 ± 1.43 | 0.23 |
| Salt intake | 9.2 ± 2.5 | 9.4 ± 2.5 | 0.67 |
Data shown are shown as the mean ± standard deviation, or numbers (%).
Paired t‐test.
Wilcoxon signed‐rank test.
BW, bodyweight; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; LnACR, logarithmic value of urine albumin‐to‐creatinine ratio; MAP, mean arterial pressure; SBP, systolic blood pressure.